Excluded
DCF
Free cash flow, growth, discount rate, and terminal growth form an intrinsic value range.
---
-
-estimated share-count samples
I
HealthcareBiotechnologyUnited States
INSM.US · Insmed Incorporated
NMS · US · USD
Latest price136.48 USD
30D+2.04%
Vs. base value-
Research summary
INSM.US latest organized financial period shows revenue lacks a complete YoY comparison and net income declined -39.73% YoY. Current price is about 136 USD, while the model base case is about -; the valuation gap needs more complete inputs. This summary is intended for public-information research and model review.
Key financial trend
Annual financial metrics with switchable views. · Unit: USD
Revenue-
Net income-1B USD
Free cash flow-968M USD
Operating cash flow-935M USD
Price trend
Price date: 2026/04/28 · Updated: 2026/04/29 07:22
Valuation model range
Hover each model row to inspect formulas and inputs.
Current price136.48 USD
Base value-
Vs. base-
Price date2026/04/28
---
-
Excluded
Owner Earnings
Uses recent net income as an owner-earnings proxy and discounts scenario growth.
---
-
-estimated share-count samples
Excluded
Reverse DCF
Solves the forward FCF growth rate implied by the current price.
Implied growth-
-
-estimated share-count samples
Excluded
Earnings Power Value
Estimates earnings power value without assuming growth.
---
-
-estimated share-count samples
Updated: 2026/04/29 07:22
Ad placement
Quarterly and annual financial table
Financial DetailsShowing latest 5 / 10
| Period | Type | Revenue | Net Income | Free Cash Flow | Diluted EPS |
|---|---|---|---|---|---|
| 2025/12/30 | Annual | - | -1B USD | -968M USD | -6.42 |
| 2024/12/30 | Annual | - | -914M USD | -706M USD | -5.57 |
| 2023/12/30 | Annual | - | -750M USD | -550M USD | -5.34 |
| 2022/12/30 | Annual | - | -482M USD | -410M USD | -3.91 |
| 2021/12/30 | Annual | - | -435M USD | -371M USD | -3.88 |
Ad placement